You are here:

MS in the media

Published on

30 January - 5 February 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

Fingolimod for PPMS trial unsuccessful

The results of the INFORMS trial (originally announced at the end of last year) have been published in the Lancet.  The three year trial showed fingolimod was no better than placebo at slowing progression or reducing atrophy

Source: News Medical

MS Trust link: Drugs in development for progressive MS

Arthritis treatment and MS risk

A Danish study of people taking TNF inhibitors as treatment for arthritis found that the risk of developing MS, whilst very low, was higher in men during the first two years of therapy

Source: MedPage Today

MS Trust link: MS Research updates

The difficulty of claiming benefits

Amy Mackelden, who has MS, writes about her long and eventually unsuccessful attempt to claim PIP, which was rejected on the basis that she didn't look fatigued enough during her assessment.

Source: New Statesman

MS Trust link: Benefits

Step training study

A small Australian study found that a home based video game approach to step training improved standing balance and coordination.  There were fewer falls in the treatment group, though this wasn't statistically significant.

Source: MSIF

MS Trust link: Exercises for people with MS

Company pulls out of female hormone treatment

A drug development company that was working on the development of Trimesta (estriol) as a treatment for relapsing remitting MS has withdrawn from the project.  Their decision was based on an analysis of the results of the trial of the drug in combination with Copaxone, which it felt wasn't significantly better than Copaxone alone.  The trial results were reported in December

Source: PR Newswire

MS Trust link: Hormones

Work and MS

Studies of a group of Americans with MS found that employment rates had fallen from 82% to below 40% since diagnosis.  Being in work and having job satisfaction were associated with higher levels of quality of life.

Source: National MS Society (USA)

MS Trust link: At work with MS

Tysabri v fingolimod

An observational study in France found that at both one year and two years of treatment, people on Tysabri had a lower relapse rate than those taking fingolimod.  They also showed fewer new lesions on MRI.  There was no difference between the drugs on measures of the change in disability measured by EDSS.  [The story uses the word 'more' in the third paragraph when presumably it should say 'fewer']

Source: News Medical

MS Trust link: MS Decisions

Indicators of risk of primary progressive MS

A US study looked at people with radiologically isolated syndrome (areas of damage visible on MRI but no symptoms and not yet diagnosed with MS).  About 12% went on to develop primary progressive MS.  These people were more likely to be men, older and to have lesions in the spinal cord

Source: National MS Society (USA)

MS Trust link: Primary progressive MS